NBTX — Nanobiotix S.A. - ADSs

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

El: kaydır · Tekerlek: yakınlaştır · Sağ eksen sürükle/tekerlek: fiyat ölçeği · Alt eksen sürükle/tekerlek: tarih ölçeği · Çift tık: otomatik ölçek · Esc iptal